chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 16.0
Sex: U
Vaccine: FLU3
Symptoms: No adverse event, Underdose
Clinical narrative: Initial misuse report received from a healthcare professional  on 13 November 2013. On unspecified date a 16 year patient received 0.25 ml of FLUZONE. Under dose was administered to the patient. No adverse event was reported. List of documents held by sender: none.
Age: 3.0
Sex: U
Vaccine: FLU3
Symptoms: No adverse event, Underdose
Clinical narrative: Initial misuse report received from a nurse on 14 November 2013. The 3-year-old patient had received FLUZONE 0.25 ml instead of the age appropriate 0.5 ml dose. No adverse event was reported. List of documents held by sender: none.
Sex: U
Vaccine: FLU3
Symptoms: Extra dose administered, No adverse event
Clinical narrative: Initial misuse report received from a nurse on 16 November 2013. The patient had received FLUZONE. It was reported that vaccine administered to patient on same day in October 2013. (No information was provided regarding the patient). No adverse event was reported. List of documents held by sender: none.
Sex: U
Vaccine: FLU3
Symptoms: Extra dose administered, No adverse event
Clinical narrative: Initial misuse report received from a healthcare professional on 11 November 2013.  It was reported that the patient had received FLUVIRIN on 3 October 2013 and FLUZONE on 21 October 2013. No adverse event was reported. List of documents held by sender: none.
Sex: U
Vaccine: DTAP, FLU3, HIBV, MNQ, TDAP, DTAP, FLU3, HIBV, MNQ, TDAP
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Initial misuse report received from a nurse on 07 November 2013. The patient had received ACTHIB, MENACTRA, DAPTACEL, FLUZONE and ADACEL. On 31 October 2013, temp went down to 33 F. On 01 November 2013, temp went down to 33F. On 04 November 2013, temp went up to 50.7 F. On 06 November 2013, the alarm went off at 29F. As of 31 October 2013, all MENACTRA were unstable. As of 06 November 2013, all products except ACTHIB are unstable for use. (No information was provided regarding the patient). No adverse event was reported. List of documents held by sender: none.
Age: 47.0
Sex: F
Vaccine: FLU3
Symptoms: Hypoaesthesia, Pain in extremity, Paraesthesia, Sensory loss
Clinical narrative: Initial report received from a patient on 20 November 2013. A female patient had received a dose of FLUZONE (lot number U11910AA, on left deltoid by intramuscular route) on 19  November 2013. Patient was allergic to penicillin. On 19 November 2013, after vaccination the patient experienced soreness in left arm. Patient stated on 20 November 2013, and experienced pain down left arm, tingling in arm and has now a feeling of numbness in arm with loss of sensation. At the time of this report the outcome of adverse event was not recovered. Documents held by sender: none.
Sex: F
Vaccine: FLU3
Symptoms: Fatigue, Headache, Impaired work ability, Paraesthesia
Clinical narrative: A female patient of unknown age, whose medical history and concomitant medications were not reported, had received a dose of FLUZONE (lot number, route and site of vaccination were not reported) on an unknown date in 2013. After receiving vaccine, later in the day (2013) she began having tingling in her extremities and chest. She felt tired and had a headache. She was sent home from work. Symptoms persisted and she seen in the ER for these same symptoms. Corrective treatment was not reported. At the time of this report the outcome of adverse events was resolved.  Documents held by sender: none.
Age: 68.0
Sex: U
Vaccine: FLU3
Symptoms: Drug administered to patient of inappropriate age, No adverse event
Clinical narrative: Initial misuse report received from a healthcare profession on 11 November 2013. On unspecified date a 68-year-old patient had received an intradermal dose of FLUZONE. Intradermal vaccines have not been established in persons less than 18 or 65 and over years of age. Thus vaccine was administered at inappropriate age. No adverse event was reported. List of documents held by sender: none.
Sex: U
Vaccine: FLU3
Symptoms: No adverse event, Underdose
Clinical narrative: Initial misuse report received from a healthcare professional (nurse) ion 18 October 2013 and the case was received on 20 March 2014 at GPV. It was reported that 4 adult patients (information regarding the patient ws not provided) had received a dose of 0.25 ml of FLUZONE (batch number, dose in series and site of administration was not reported) on an unspecified date. No adverse event was reported. List of documents held by sender: none.
Age: 46.0
Sex: F
Vaccine: FLU3
Symptoms: Asthenia, Impaired work ability, Oedema peripheral, Pyrexia
Clinical narrative: Initial report received from a nurse on 03 December 2013. Medical history included thyroiditis, borderline high blood pressure. A 45 year old female patient had received a dose of FLUZONE (lot number unknown, intramuscularly on left deltoid on an unspecified date in 2011). On an unspecified date (2011), after receiving vaccine the patient developed a major swelling under her arm in the armpit area. The swelling was so large she had to hold er arm up., couldn't put it down to the side. She had generalized weakness and fever of 102 F. She was unable to work for one week. At the time of this report the outcome of adverse event were recovered.  Documents held by sender: none.
Sex: M
Vaccine: FLU3
Symptoms: Injection site pain
Clinical narrative: Initial report reported by physician on 26-Nov-2013: A unknown age of male patient, medical history and concomitant medical history was unknown , received dose of FLUZONE at unknown anatomical site on unspecified date. It was reported that patient experienced sever deltoid pain after 7 days after receiving vaccination. Event outcome was unknown. List of documents held by sender: none.
Sex: U
Vaccine: FLU3
Symptoms: Expired product administered, No adverse event
Clinical narrative: Initial misuse report received from a pharmacist on 07 November 2013.  The 3 female patients had received FLUZONE. It was reported that medical assistant administered expired dose of vaccine to pregnant patients. No adverse event ws reported. List of documents held by sender: none.
Sex: M
Vaccine: FLU3
Symptoms: Injection site erythema, Injection site induration, Injection site nodule, Injection site swelling
Clinical narrative: Initial report received from a non-health care professional on 25-Nov-2013. A male patient, whose age, medical history and concomitant medications were not reported, had received a dose of FLUZONE (lot number, route, and site of vaccination were not reported), on an unspecified time. On an unspecified date, after receiving vaccine the patient experienced a real area at injection site that has been getting larger, more red, swollen and has a hard knot under the skin which is about the width of a half dollar coins. Corrective treatment was not reported. At the time of this report the outcome of adverse event was unknown. Documents held by sender: none.
Sex: F
Vaccine: FLU3
Symptoms: Rash, Swelling
Clinical narrative: Initial report received from a nurse on 21 November 2013. A female patient whose age, concomitant medications were not reported, had received a dose of iinfluenza USP trival a-b subvirion vaccine (flu vaccine) (lot # and route unknown) on an unknown date. On an unknown date after receiving vaccine the patient experienced rash and swelling. Patient was allergic to gelatin. At the time of this report the outcome of adverse events was recovered. Documents held by sender: none.
Sex: F
Vaccine: FLU3, FLUX
Symptoms: Abdominal pain, Diarrhoea, Injection site induration, Injection site inflammation, Injection site nodule
Clinical narrative: A female patient, whose age, medical history included allergic to monosodium glutamate, thimerosal, demerol, morphine, stadol, versed, intravenous contrast dye and concomitant medications were not reported, had received a dose of influenza USP trival a-b sub virion vaccine (flu vaccine) (lot number, route and site of vaccination were not reported), on an unspecified date in 2012. On an unspecified date in 2012, after receiving vaccine the patient experienced abdominal pian, diarrhea, and vomiting that lasted 2 to 3 days. patient had flu vaccine this year but did not receive a flu vaccine that had a preservative. She did not experience any abdominal pain, diarrhea after this year's flu vaccine. She only had hard knot and inflammation at site for this year's flu vaccine. Thein she stated she did throw up once today 25 November 2013, but thinks that was related to her "sensitive stomach" and the food she ate at a restaurant last night. At the time of this report the outcome of adverse event were recovered. Documents held by sender: none.
Sex: F
Vaccine: FLU3, FLUX
Symptoms: Vomiting
Clinical narrative: A female patient, whose age, medical history included allergic to monosodium glutamate, thimerosal, demerol, morphine, stadol, versed, intravenous contrast dye and concomitant medications were not reported, had received a dose of influenza USP trival a-b sub virion vaccine (flu vaccine) (lot number, route and site of vaccination were not reported), on an unspecified date in 2012. On an unspecified date in 2012, after receiving vaccine the patient experienced abdominal pian, diarrhea, and vomiting that lasted 2 to 3 days. patient had flu vaccine this year but did not receive a flu vaccine that had a preservative. She did not experience any abdominal pain, diarrhea after this year's flu vaccine. She only had hard knot and inflammation at site for this year's flu vaccine. Thein she stated she did throw up once today 25 November 2013, but thinks that was related to her "sensitive stomach" and the food she ate at a restaurant last night. At the time of this report the outcome of adverse event were recovered. Documents held by sender: none.
Sex: F
Vaccine: FLU3, FLUX
Symptoms: Abdominal pain, Diarrhoea, Vomiting
Clinical narrative: A female patient, whose age, medical history included allergic to monosodium glutamate, thimerosal, demerol, morphine, stadol, versed, intravenous contrast dye and concomitant medications were not reported, had received a dose of influenza USP trival a-b sub virion vaccine (flu vaccine) (lot number, route and site of vaccination were not reported), on an unspecified date in 2012. On an unspecified date in 2012, after receiving vaccine the patient experienced abdominal pian, diarrhea, and vomiting that lasted 2 to 3 days. patient had flu vaccine this year but did not receive a flu vaccine that had a preservative. She did not experience any abdominal pain, diarrhea after this year's flu vaccine. She only had hard knot and inflammation at site for this year's flu vaccine. Thein she stated she did throw up once today 25 November 2013, but thinks that was related to her "sensitive stomach" and the food she ate at a restaurant last night. At the time of this report the outcome of adverse event were recovered. Documents held by sender: none.
Age: 59.0
Sex: F
Vaccine: FLU3
Symptoms: Gait disturbance, Gastric disorder, Malaise, Nausea
Clinical narrative: Initial report received from a reporter on 15 November 2013. A 59-year-old female patient, whose medical history included NS and whose age and concomitant mediations were not reported, had received a dose of influenza USP trival a-b subvirion vaccine (flu vaccine) on 30  September 2013. On 08 October 2013, after receiving vaccine the patient feeling sick to her stomach and she has stomach issues. The patient has trouble walking. The patient also did not feel well. Corrective treatment ws not reported. At the time of this report the outcome of adverse event ws not resolved. Documents held by send: none.
Age: 3.0
Sex: U
Vaccine: FLU3
Symptoms: No adverse event, Underdose
Clinical narrative: This case is related with case # 2013SA115640. Ini6tial medication error report received from a physician on 05 November 2013. The 03 year old unknown gender patient received FLUZONE 0.25 ml (lot # was unknown) at unknown site on 04-Nov-2013. (No information was provided regarding the patient). No adverse event was reported. List of documents held by sender: none.
Age: 42.0
Sex: F
Vaccine: FLU3
Symptoms: Pain in extremity
Clinical narrative: Initial report received from a pharmacist on 19 November 2013. A 43 year old female patient. whose medical history and concomitant medications were not reported, had received a dose of FLUZONE (lot number UH904AA) (site of vaccination were not reported) intramuscularly on 21 September 2013. The nurse reported that patient's entire arm became sore on the same day (21 September 2013) as the vaccine was administered. Symptom has not subsided. Corrective treatment was not reported. At the time of this report the outcome of adverse event was not resolved. Documents held by sender: none.
Sex: M
Vaccine: FLU3
Symptoms: Headache, Laboratory test, Myalgia
Clinical narrative: Initial report received from consumer's mother on 19 November 2013. The male patient received FLUZONE (lot number and expiration date unknown) intramuscularly in left deltoid (dose number not reported) about eight days ago and 24 hours after vaccination began experiencing headache and generalized muscle aches. The headache ws resolved but generalized muscle aches continue to today (19-Nov 2013). The patient took TYLENOL, ALEIVE. The patient's lab work was done. Documents held by sender: none.
Sex: U
Vaccine: DTAPIPVHIB, FLU3, FLU3, HIBV, IPV, MNQ, TDAP
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Initial misuse report received on 02 December 2013 from a health care professional. A patient's whose gender, age, medical history and concomitant mediations were not reported, received a dose of FLUZXONE, FLUZONE ID, Tubersol, Pentacef, Anacel, Enactor, IPOL and Acthib (lot  number, route and site of vaccination was not reported) on an unspecified date. It was reported that the temperature was reached 32 F for  (4-8 hours over a month time period. As of 02 December 2013. Patient did not have any adverse events.  List of documents held by sender: none.
Sex: U
Vaccine: FLU3
Symptoms: Incorrect product storage
Clinical narrative: Initial report received from healthcare professional on 11 December 2013. On an unknown date, FLUZONE exposure to OC for 3 weeks and advised to discard. If patients were vaccinated with unstable vaccine, the CDC states, Damage to the immunogenicity of a vaccine exposed to temperature outside of the recommended range might not be apparent visually. As a general rule, vaccines that have been administered guidance is available from the state health department or CDC. Vaccine exposed to inappropriate temperatures that is inadvertently administered should generally be repeated. Clinicians should consult with state or local health departments in these situations. Laboratory investigation and corrective treatment were not reported. Documents held by sender: none.
Sex: U
Vaccine: DTAPIPVHIB, FLU3, HIBV, MNQ
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Initial misuse report received from a healthcare professional. The patient had received Acthib, FLUZONE, MENACTRA and PENTACEL.  It was reported that on 11 October 2013 temperature was as low as 32F and Acthib and FLUZONE was ok for use. (No information was provided regarding the patient). No adverse event was reported. List of documents held by sender: none.
Age: 61.0
Sex: U
Vaccine: FLU3
Symptoms: Nausea
Clinical narrative: Initial information received from a consumer (the patient) on 09 December 2013. A 61-years-old patient had received a dose of 2.5 ml of FLUZONE (dose number, route, and site of administration unknown) on 09 December 2013. The patient had a lifetime (since childhood) history of egg allergy. At one paint, the patient used to keep in Epi-Pen handy and have been in the ER several times in lifetime due to inadvertent consumption of food with egg ingredients. Over the past 5 years or so, tolerance to eggs has improved such that the patient kept away from actual eggs but have been able to eat such things as bread crumbs that have eggs listed as an ingredient with no ill effect.  The patient also never had a problem with food that was "manufactured or equipment that processes eggs" etc. Prior to 2012, the patient had never received a fu shot. However, was motivated to look into getting a flu vaccine by a high local incidence of flu last year. After doing some online research the patient came across a study. It gave enough  personal confidence to get a FLUZONE vaccine from a local pharmacy by not admitting allergy to eggs. On an unspecified date, the patient experienced nausea. Laboratory tests and corrective treatment were not reported. At the time of this report, the outcome was unknown. Documents held by sender: none.
Age: 83.0
Sex: M
Vaccine: FLU3
Symptoms: Blood test normal, Brain scan normal, Diplopia, Fall, Insomnia
Clinical narrative: Initial report received from a consumer on 09-Dec-2013. A 83 year old male received influenza USP trivial A-B sub virion vaccine (lot # and expiration date unknown) on 23-Oct-2013. Within 24 hours of vaccination, on 24-Oct-2013, the patient had double vision. The event was ongoing at the time of the report. Documents held by sender: none.   Follow-up information was received on 18 February 2014: It was reported that the patient had additional symptoms. He was often falling down, initially he was sleeping for 15 hours a night but now sleeping only for 8 hours. He had seen his physician which sent him for a "brain scan with dye". The physician told him the scan was negative. He had persistent double division that was frustrating to him. The patient told that his single eye vision was intact, referring to which when he covers one eye, he could see normally. The physician also prescribed a one week course of Ciprofloxacin (Cipro) and some eye drops, neither of which resolved the double vision or the falling down.   Follow up information received from consumer on 25 February 2014: The patient had received a first dose of vaccine intramuscularly in the left arm. It was reported that prior to the vaccine the patient had a good eye exam. The next day after the vaccine the patient had double vision and were sleeping for 15 hours a day. The physician gave him CIPRO as corrective treatment. The patient, then went for 2 brain scans which "showed nothing". The patient had blood tests that "showed nothing". The was now sleeping only 20 hours a day. The dog licked his eyes and his vision improved for a few hours after that. Every time the dog licks his eyes the vision improved for a few hours. On an unspecified date, the patient had recovered from events.
Sex: U
Vaccine: FLU3
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Initial misuse report received from a healthcare professional on 12-Dec-2013. The patient had received FLUZONE. The nurse reported that temperatures went down to 27 F and vaccine administered to the patient. (No information was provided regarding the patient). No adverse event was reported. List of documents held by send: none.
Sex: U
Vaccine: FLU3
Symptoms: Drug administered to patient of inappropriate age, No adverse event
Clinical narrative: Initial misuse report received from a consumer on 04 December 2013.  A 8 week old child had received a 0.25 ml of FLUZONE. (No information was provided regarding the patient). No adverse event was reported. List of documents held by sender: none.
Age: 65.0
Sex: U
Vaccine: FLU3
Symptoms: Extra dose administered, No adverse event
Clinical narrative: Initial misuse report received from a nurse on 12 December 2013.  A 65-years-old patient had received FLUZONE in October in extra dose. (No information was provided regarding the patient). No adverse event was reported. List of documents held by sender: none.
Age: 4.0
Sex: U
Vaccine: FLU3
Symptoms: No adverse event, Underdose
Clinical narrative: Initial misuse report received from a nurse on 10 December 2013. A 4-year-old child patient had received FLUZONE 0.25 ml instead of 0.5 ml. No adverse event was reported. List of documents held by sender: none.
Age: 4.0
Sex: U
Vaccine: FLU3
Symptoms: No adverse event, Underdose
Clinical narrative: Initial misuse report received from a nurse on 02 December 2013.  A 4-year-old child patient had received 0.25 ml of FLUZONE. (No information was provided regarding the patient). No adverse event was reported. List of documents held by sender: none.
Age: 3.0
Sex: U
Vaccine: FLU3
Symptoms: Incorrect dose administered, No adverse event
Clinical narrative: Initial medication error received on 02 December 2013 from nurse. An under 3 year patient whose gender, medical history and concomitant mediations were not reported, received a dose of FLUZONE (route, lot number and site of vaccination was not reported) on an unknown date. Patient received 0.5 ml to who was under age 3. Patient did not have any adverse events. List of documents held by sender: none.
Age: 3.0
Sex: U
Vaccine: FLU3
Symptoms: No adverse event, Underdose
Clinical narrative: Initial medication error report received on 03 December 2013 from nurse. A 3 year child patient whose gender, medical history and concomitant medications were not reported, received a dose of FLUZONE (route, lot number and site of vaccination  was not reported) on an unknown date. Reporter stated that child received 0.25 ml FLUZONE to child. Patient did not have any adverse events. List of documents held by sender: none.
Age: 3.0
Sex: U
Vaccine: FLU3
Symptoms: Inappropriate schedule of drug administration, No adverse event
Clinical narrative: Initial medication error report received on 02 December 2013 from nurse.  A 3 year child patient whose gender, medical history and concomitant medications were not reported, received a dose of FLUZONE (route, lot number and site of vaccination was not reported) on an unknown date. Reporter stated that child received two doses of 0.25 ml instead of 0.5 ml one month. Patient did not have any adverse events. List of documents held by sender: none.
Sex: U
Vaccine: FLU3
Symptoms: No adverse event, Underdose
Clinical narrative: Initial medication error report received on 09 December 2013 from nurse. A patient whose age, gender, medical history and concomitant medications were not reported, received a dose of FLUZONE (route, lot number and site of vaccination was not reported) on an unknown date. Reporter stated that adult consumer received 0.25 ml. Patient did not have any adverse events. List of documents held by sender: none.
Sex: U
Vaccine: FLU3
Symptoms: Incorrect route of drug administration, No adverse event
Clinical narrative: Initial medication error report received on 05 December 2013 from nurse. A patient whose age, gender, medical history and concomitant medications were not reported, received a dose of FLUZONE (route, lot number and site of vaccination was not reported) on an unknown date. Reporter stated that consumer received incorrect route of vaccination. Patient did not have any adverse events. List of documents held by sender: none.
Age: 2.8
Sex: U
Vaccine: FLU3
Symptoms: Incorrect dose administered, No adverse event
Clinical narrative: Initial misuse report received from a healthcare professional on 04 December 2013. On unspecified date a 34 month-old patient had received 0.5 ml of FLUZONE. Wrong dose was administered to the patient. No adverse event was reported. List of documents held by sender: none.
Age: 18.0
Sex: U
Vaccine: FLU3
Symptoms: Extra dose administered, No adverse event
Clinical narrative: Initial medication error report received on 03 December 2013 from nurse. An 18 year patient whose gender, medical history and concomitant medications were not reported, received a dose of FLUZONE (route, lot number and site of vaccination was not reported) on 03 December 2013. Reporter stated that consumer received one extra dose of FLUZONE. Patient already vaccinated in November and again in 03 December 2013. Patient did not have any adverse events. List of documents held by sender: none.
Age: 2.8
Sex: U
Vaccine: FLU3
Symptoms: Incorrect dose administered, No adverse event
Clinical narrative: Initial medication error report received on 04 December 2013 from an office person (medical assistant). A 34 months infant patient whose gender, medical history and concomitant medications were not reported, received a dose of FLUZONE (route, lot number and site of vaccination was not reported) on an unspecified date. Reporter stated that consumer received 0.5 ml instead of 0.25 ml. patient did not have any adverse events. List of documents held by sender: none.
Age: 3.0
Sex: U
Vaccine: FLU3
Symptoms: No adverse event, Underdose
Clinical narrative: Initial report received from a healthcare professional on 04 December 2013. A 3 year old 1 month old child patient had received a 0.25 ml  influenza USP trival A-B subvirion. (No information was provided regarding the patient). No adverse event was reported. List of documents held by sender: none.
Sex: U
Vaccine: FLU3
Symptoms: Inappropriate schedule of drug administration, No adverse event
Clinical narrative: Initial misuse report received from a healthcare professional. The child patient needed two doses FLUZONE and received first dose on 04th October and second dose on 25th October week earlier than they should have. This was an invalid schedule. (No information was provided regarding the patient). No adverse event was reported. List of documents held by sender: none.
Sex: U
Vaccine: FLU3, TDAP
Symptoms: Incorrect product storage, No adverse event, Tuberculin test
Clinical narrative: Initial misuse report received from a healthcare professional on 03 December 2013. Four patients had received doses from open vials/unstable FLUZONE, TUBERSOL and ADACEL. (No information was provided regarding the patient). No adverse event was reported. List of documents held by sender: none.
Age: 17.0
Sex: F
Vaccine: FLU3
Symptoms: Drug administered at inappropriate site, Injection site reaction, Tendonitis
Clinical narrative: Initial report received from a health care professional on 30 January 2014. A female patient, whose demographic details including age, date of birth and initials not reported had received a dose of FLUZONE (dose number, lot number, route and site of vaccination not reported) on an unspecified date. The patient had received the vaccine in the tendon of the rotator cuff and the patient had experienced inflammation of her tendon. Corrective treatment and laboratory details were not reported. At the time of this report the outcome of the event was unknown. Documents held by sender: none.  Follow up information was received on 07 April 2014: It was updated that the patient's date of birth was on 17 January 1997 and the age was 17 years at the time of the report.
Sex: U
Vaccine: FLU3
Symptoms: Extra dose administered, No adverse event
Clinical narrative: Initial misuse report received from a non healthcare professional on 09 January 2014. A patient (no information was provided regarding the patients) had received 2 doses of FLUZONE on 08 January 2014 that was shipped on 06 January 2014. No adverse event was reported. Documents held by sender: none.
Sex: U
Vaccine: FLU3
Symptoms: Extra dose administered, No adverse event
Clinical narrative: Initial misuse report received from a healthcare professional on 06 January 2014. A child (date of birth and gender was not reported) had received a dose of FLUZONE. It was reported the patient had received 3 doses of FLUZONE instead of 2 doses. No adverse event was reported. Documents held by sender: none.
Sex: U
Vaccine: FLU3
Symptoms: No adverse event, Underdose
Clinical narrative: Initial misuse report received from a Healthcare professional on 06 January 2014. A 4-year-old patient had received first dose of 0.25 ml of FLUZONE last year. No adverse event was reported. Documents held by sender: none.
Sex: F
Vaccine: FLU3
Symptoms: Extra dose administered, No adverse event
Clinical narrative: Initial misuse report received from a non-healthcare professional on 09 January 2014. A female patient (no information was provided regarding the patient(s) had received a dose of FLUZONE on an unspecified date and then it was found that the patient had received a does of FLUZONE on an unspecified date in November 2013. No adverse event was reported. Documents held by sender: none.
Age: 69.0
Sex: U
Vaccine: FLU3
Symptoms: Drug administered to patient of inappropriate age
Clinical narrative: Initial misuse report received from a healthcare professional on 09 January 2014. A 69-year-old patient (gender: not reported had received  a dose of FLUZONE. No adverse event was reported. Documents held by sender: none.
Age: 2.0
Sex: U
Vaccine: FLU3
Symptoms: Incorrect dose administered
Clinical narrative: Initial misuse report received from a healthcare professional on 13 January 2014. A 2-year-old patient had received a 0.5 ml of FLUZONE adult dose was administered to a child. It's an incorrect dose administered. No adverse event was reported. List of documents held by sender: none.
Sex: U
Vaccine: FLU3
Symptoms: Extra dose administered, No adverse event
Clinical narrative: Initial misuse report received from a healthcare professional on 07 January 2014.  A 12-month-old male patient had received 0.25 ml of FLUZONE first dose on 11 November 2013 and second dose on 17 October 2013 and the patient had also received 0.5 ml third dose on an unspecified date. No adverse event was reported. List of documents held by sender: none.
Age: 1.0
Sex: U
Vaccine: FLU3
Symptoms: No adverse event, Overdose
Clinical narrative: Initial misuse report received from a healthcare professional on 14 January 2014. An 11-month-old patient had received a 0.5 ml dose of FLUZONE on an unspecified date. It ws reported that FLUZONE 0.5 ml was administered to an 11 month old who should have received 0.25 ml. No adverse event was reported. List of documents held by sender: none.
Sex: U
Vaccine: FLU3
Symptoms: Inappropriate schedule of drug administration
Clinical narrative: Initial misuse report received from a healthcare professional on 14 January 2014. A dose of FLUZONE was unsure if they received it before, but if they did it would have been before 6 months of age with no adverse event. The child has not had any reaction to the alleged vaccine in October. Not really sure if the child received it. The child should receive two vaccine 4 weeks apart this year. List of documents held by sender: none.
Sex: U
Vaccine: FLU3
Symptoms: Extra dose administered, No adverse event
Clinical narrative: Initial misuse report received from a healthcare professional on 07 January 2014. A patient received a dose of FLUZONE on 26 September 2013 and it was reported that the patient had received a dose of FLUZONE HD one month ago. No adverse event was reported. Documents held by sender: none.
Sex: U
Vaccine: FLU3
Symptoms: Expired product administered
Clinical narrative: Initial case was received from a healthcare professional on 09 January 2014. This patient of unknown age and gender whose medical history and concomitant medication was not reported had received a FLUZONE (dose, batch number, route and anatomical site of administration not reported) which was expired two years, old box in the refrigerator.
Age: 30.0
Sex: F
Vaccine: FLU3
Symptoms: Rash, Rash erythematous, Rash pruritic
Clinical narrative: Initial case was received from a none healthcare professional on 20 January 2014. A 30-year-old female patient whose medical history and concomitant medication was not reported had received an intramuscular FLUZONE, batch number, dose and anatomical site of administration not reported) on 18 January 2014. The patient was allergic to Ciprofloxacin. The next morn. On 19 January 2014, in the morning after receiving FLUZONE, she developed itchy, red raised rash, on back under arms and a tiny bit on chest sides. On 19 January 2014, the patient took an antibiotic that was completed two days before the flu vaccine. She consulted MD. No treatment was prescribed. The event was not recovered. List of documents held by sender: none.
Sex: F
Vaccine: FLU3
Symptoms: Adverse event
Clinical narrative: Initial report received from a healthcare professional (patient's father) on 15 January 2014. A female patient (date of birth and age at the time of event was not reported) had received a dose of FLUZONE (batch number, dose in series, route and site of administration was not reported) on an unspecified date. The patient medical history and concomitant medications were not reported. On an unspecified date, something happened to the patient. The patient's complementary investigations and corrective medications were not reported.  The outcome of event was unknown. Documents held by sender: none.
Sex: U
Vaccine: FLU3
Symptoms: Adverse event
Clinical narrative: Initial report received from a healthcare professional on 07 January 2014. A patient of unspecified demographics, whose medical history and concomitant medications were not reported, had received a dose of FLUZONE (intradermal, dose number, route, anatomical site of vaccination and batch number were not reported). On an unspecified date, the patient developed adverse event nos. Corrective treatments and laboratory investigations were not reported. As of this report, the outcome of the events was not reported. Documents held by sender: none.
Age: 50.0
Sex: F
Vaccine: FLU3
Symptoms: Chest discomfort
Clinical narrative: Initial report received from a healthcare professional on 03 January 2014. A 50-year-old female patient had received an intramuscular dose of FLUZONE (batch number, UH910AA, expiry date; 30 June 2014 and does number was not reported) in the left deltoid on 02 January 2014. The patient had no illness at time of vaccination and had a medical history of asthma. Concomitant medications were not reported. On 02 January 2014, same day of vaccination, the patient experienced tightness in the chest, unknown if the tightness was constant or comes and goes. No laboratory tests were performed and corrective treatments were not reported. At the time of this report, the outcome was unknown. List of documents held by sender: none.  Follow-up information was received from healthcare professional on 11 August 2014. It was reported that the patient was recovered from event (date unspecified). Documents held by sender: none.
Age: 15.0
Sex: F
Vaccine: FLU3, MNQ
Symptoms: Exposure during pregnancy, No adverse event, Pregnancy test urine positive
Clinical narrative: Initial report received from the healthcare professional on 16-Dec-2013. A female patient age unknown, medical history and concomitant medications were not reported, had received MENACTRA (batch number U4686AA, expiry date unknown) and FLUZONE (batch number UH900AA, expiry date unknown) intramuscular on 11 November 2013. The patient was pregnant while receiving the both of the vaccine. The patient did not have any  other adverse event while receiving vaccine. List of documents held by sender: none.  Follow-up information received from healthcare professional on 15 January 2014. Father's health status was reported as unknown. The patient did not have any family history of congenital abnormality. The patient's last menstrual period was reported as 04 November 2014. The patient did not receive any treatment for infertility with no previous pregnancies. The patient received MENACTRA in left forearm. The patient received Methyl Phenidate 20 mg from 11 November 2013 to 12 December 2013 for ADD. The patient did not experience any non-serious adverse event. The patient carried only urine pregnancy test in office and will be going to an OB/GYN for prenatal care without any complications in pregnancy.
Sex: F
Vaccine: FLU3
Symptoms: Urticaria
Clinical narrative: Initial report received from a healthcare professional on 16 December 2013. A female patient of unknown age had received an intradermal first dose of FLUZONE (lot number: unknown) on last year. Last year, the patient had hives. Laboratory investigations and corrective medications were not reported. At the time of this report the patient recovered from the event. Documents held by sender: none.
Age: 59.0
Sex: F
Vaccine: FLU3
Symptoms: Injected limb mobility decreased, Injection site erythema, Injection site swelling, Swelling
Clinical narrative: Initial report received from non-health care professional on 16-Dec-2013. A 58 years old female patient, medical history included hypertension and migraine, concomitant medications were not reported, had received FLUZONE (batch number UH909AB, expiry date September 2014) intramuscular in the left deltoid right arm on 06 September 2013. On 06 September 2013 1 hour after vaccination, the patient's the left arm where she got the flu shot got bigger between elbow and shoulder. She went to the pharmacist who told her to go  home and take a Benadryl which she did. The swelling then went up her neck and 4 inches around injection site was solid red and she could not lift her arm. She then went to the ER. Three days later the swelling started to go down. All symptoms are now gone. The events were recovered at the time of this report. List of documents held by sender: none.
Sex: U
Vaccine: FLU3
Symptoms: Poor quality drug administered
Clinical narrative: Initial report received from a healthcare professional on 02 December 2013. Patients received FLUZONE and the doses were drawn up the day before and used. (No information was provided regarding the patient). No adverse event was reported. List of documents held by sender: none.
Sex: F
Vaccine: FLU3
Symptoms: Night sweats
Clinical narrative: Initial report received from a healthcare professional on 20 February 2019. An adult female patient, whose date of birth, age, medical history and concomitant medication were unknown, had received a dose of FLUZONE (lot number: unknown, dose number, route and anatomical site of administration were reported as "NA") on an unspecified date . On an unspecified date, same day after vaccination, the patient experienced night sweat. Laboratory investigations and corrective treatments were not reported. At the time of this report, the patient had not recovered from events. Documents held by sender: none
Age: 60.0
Sex: F
Vaccine: FLU3
Symptoms: Injection site erythema, Wrong drug administered
Clinical narrative: Initial misuse report received from a healthcare professional on 20 February 2014. (Reference number: 14-0110). A 60-year old female patient had received dose of FLUZONE (batch number UH920AC, expiration date 30-June-2014), route of vaccination not reported) in the left forearm SQ on 19 February 2014. The medical history of the patient included allergic to Penicillin and concomitant medications were not reported. The patient does not have any illness at the time of vaccination. it was reported that on 19 February 2014 accidentally used FLUZONE MDV instead of Tubersol for PPD. Inserted 0.1 ml into the left forearm SQ. Patient developed redness at insertion site. The nurse plans to advise patient to use cold compresses, Motrin. No other details about the area of redness. The laboratory investigation was not reported.  At the time of this report the outcome of the adverse event was not resolved. Documents held by sender: none.
Age: 1.9
Sex: U
Vaccine: FLU3
Symptoms: Extra dose administered, No adverse event
Clinical narrative: Initial misuse report received from a healthcare professional on 6 February 2014. A 23-months-old patient had received second dose of FLUZONE on an unspecified date when second dose was not indicated. No adverse event was reported. List of documents held by sender: none.
Age: 1.9
Sex: U
Vaccine: FLU3
Symptoms: Extra dose administered, No adverse event
Clinical narrative: Initial misuse report received from a healthcare professional on 16 February 2014. A 21-months old patient had received second dose of FLUZONE on an unspecified date when second dose was not indicated. No adverse event was reported. List of documents held by sender: none
Sex: U
Vaccine: FLU3
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Initial misuse report received from a healthcare professional on 13 February 2014. It was reported that the patient (no information was provided) regarding the patient) had received a dose of FLUZONE that was exposed to too low temperature (29.8F) for 2.5 hours. No adverse event was reported. Documents held by sender: none
Age: 0.8
Sex: U
Vaccine: FLU3
Symptoms: Drug administered to patient of inappropriate age, No adverse event
Clinical narrative: Initial misuse report received from a healthcare professional on 14 February 2014. A 08-month-old patient received 0.5 ml dose of FLUZONE (no information was provided regarding the patient) on an unspecified date. No adverse event was reported. List of documents held by sender: none
Age: 2.0
Sex: F
Vaccine: FLU3
Symptoms: Incorrect dose administered, No adverse event
Clinical narrative: Initial misuse report received from a healthcare professional on 07 February 2014. A 24 months old female patient received FLUZONE 0.5 ml instead of 0.25 ml. No adverse event was reported. List of documents held by sender: none
Age: 2.0
Sex: U
Vaccine: FLU3
Symptoms: Incorrect dose administered
Clinical narrative: Initial case was received from a health-care person on 07 February 2014. A 02-year-old patient of unknown gender whose medical history and concomitant medication was not reported had received FLUZONE 0.5 ml instead of .25 ml for the first dose (lot number, route and site of administration not reported) on an unspecified date. The list of documents held by sender: none
Sex: U
Vaccine: FLU3
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Initial case of medication error was received  from a healthcare professional on 12 Feb 2014. A patient whose demographics detail including (gender and age) medical history and concomitant medication were not reported received a dose of FLUZONE on an unspecified date (route, dose, site and batch number was not reported). It was reported that on an unspecified date FLUZONE had been administered to the patient after it was stored improperly below recommended temperatures (FLUZONE reached 1 degree Celsius for 72 hours on 29 separate occasions in two month period). No information regarding adverse event was reported. Laboratory investigations and corrective treatment were not reported. At the time of report outcome of event was unknown . List of documents held by sender: none.
Age: 52.0
Sex: F
Vaccine: FLU3, PNC13
Symptoms: Pain in extremity, Peripheral swelling, Skin reaction, Skin warm
Clinical narrative: Initial report received from a consumer on 06 February 2014. A patient (demographical details was not reported), whose medical history and concomitant medications were not reported, had received FLUZONE (batch number: UH889A, Exp. Date: 10 JUN 2014, route of vaccine administrtaion was not reported) in the right arm and had received Pneumococcal (Polysaccharide) ( 23 Sereotypres) vaccine; pneumonia shots (batch number, route of vaccine administrtaion was not reported) in right arm, both on unspecified dates.  On an unspecified date, the patient experience arm to swell and was red with fever in it. As a corrective treatment, the patient put ice on it for the swelling and it  hurts for 5 days. Laboratory data were not reported. As of 06 February 2014, the outcome was unknown. Documents held by sender: none.
Age: 51.0
Sex: F
Vaccine: FLU3
Symptoms: Hypoaesthesia, Injection site erythema, Injection site induration, Injection site pruritus, Injection site swelling
Clinical narrative: Initial case was received from a non-healthcare professional on 05 February 2014. A 51-year-old female patient whose medical history and concomitant medication was not reported had received an intramuscular FLUZONE (batch number U4698EA, dose not reported) in the right deltoid on 30 January 2014. On 30 January 2014, the patient experienced swollen, hard, red, itchy and hot to touch area of 2 inches around injection site; and lasted 3 days. On 03 February 2014, the toes of right foot started to feel numb. It was reported that numbness feeling has extended to entire right foot up to calf area and numbness has not affected the ability to walk. The patient can walk. No laboratory investigations or corrective treatment was reported.  The outcome of the event ws not recovered. The list of documents held by sender: none.
Age: 51.0
Sex: F
Vaccine: FLU3
Symptoms: Injection site warmth
Clinical narrative: Initial case was received from a non-healthcare professional on 05 February 2014. A 51-year-old female patient whose medical history and concomitant medication was not reported had received an intramuscular FLUZONE (batch number U4698EA, dose not reported) in the right deltoid on 30 January 2014. On 30 January 2014, the patient experienced swollen, hard, red, itchy and hot to touch area of 2 inches around injection site; and lasted 3 days. On 03 February 2014, the toes of right foot started to feel numb. It was reported that numbness feeling has extended to entire right foot up to calf area and numbness has not affected the ability to walk. The patient can walk. No laboratory investigations or corrective treatment was reported.  The outcome of the event ws not recovered. The list of documents held by sender: none.
Age: 41.0
Sex: F
Vaccine: FLU3
Symptoms: Pruritus, Rash erythematous, Rash generalised
Clinical narrative: Initial case was received from a healthcare professional on 03 February 2014.  A 41-year-old male patient had medical history of allergic to iodine and shell fish, with no concomitant medication reported had received FLUZONE intramuscularly on left deltoid 23 January 2014 (batch number UH895AA). It was reported that on 25 January 2014 patient developed red patches on her neck, chest, stomach, arms, and back and experienced extremely itchy. No laboratory investigation and corrective treatment ws reported. At the time of report outcome of the event was recovered. Lit of documents held by sender: none
Age: 4.0
Sex: U
Vaccine: FLU3
Symptoms: No adverse event, Underdose
Clinical narrative: Initial misuse report received from a healthcare professional on 26 September 2013. A 4 year old patient had received FLUZONE 0.25 ml instead of 0.5 ml. it's an under dose. No adverse event was reported. List of documents held by sender: none
Age: 3.0
Sex: U
Vaccine: FLU3
Symptoms: No adverse event, Underdose
Clinical narrative: Initial misuse report received from a healthcare professional on 26 September 2013. A child of (age reported 3) unknown gender received FLUZONE 0.25 ml on an unknown date. The patient received incorrect dose of vaccine. No adverse event was reported. The list of documents held by sender: none.
Age: 0.4
Sex: U
Vaccine: FLU3
Symptoms: Drug administered to patient of inappropriate age
Clinical narrative: Initial misuse report received from a healthcare professional (nurse) on 25 September 2013 and the case was received on 21 March 2014 at GPV. A 04-month-old patient had received a dose of 0.25 ml of FLUZONE (batch number, route, dose in series and site of administration as not reported) on an unspecified date. List of documents held by sender: none
Sex: U
Vaccine: FLU3
Symptoms: Incorrect route of drug administration, No adverse event
Clinical narrative: Initial misuse report received from a healthcare professional on 18 September 2013. A patient had received FLUZONE subcutaneously in arm. It's an inappropriate route of vaccination. No adverse event was reported. List of documents held by sender: none
Sex: U
Vaccine: FLU3
Symptoms: Expired product administered, No adverse event
Clinical narrative: Initial misuse information was received from a healthcare professional in on 23 Sep 2013. A patient whose demographic details, medical history and concomitant medication were not reported received a dose of FLUZONE on an unspecified date. Route, site, dose and batch number not reported). It was reported that on an unspecified date patient received expired dose of vaccination. Laboratory investigation were not reported. No adverse event was reported. List of documents held by sender: none
Age: 1.8
Sex: U
Vaccine: FLU3
Symptoms: Incorrect dose administered, No adverse event
Clinical narrative: Initial misuse information was received from a healthcare professional in on 26 Sep 2013. A 20 month old patient whose demographic details, medical history and concomitant medications were not reported received a 0.5 ml dose of FLUZONE on an unspecified date. (Batch number not reported). It was reported that on an unspecified date patient received incorrect dose of vaccination. Laboratory investigation were not reported. No adverse event was reported. List of documents held by sender: none